Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

Noeparast, Amir; Teugels, Erik; Giron, Philippe; Verschelden, Gil; De Brakeleer, Sylvia; Decoster, Lore; De Grève, Jacques

Noeparast, Amir; Teugels, Erik; Giron, Philippe; Verschelden, Gil; De Brakeleer, Sylvia; Decoster, Lore; De Grève, Jacques.

Afiliação

Noeparast A; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Teugels E; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Giron P; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Verschelden G; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
De Brakeleer S; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
Decoster L; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.
De Grève J; Laboratory of Molecular Oncology and Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium.

Oncotarget ; 8(36): 60094-60108, 2017 Sep 01.

Article em En | MEDLINE | ID: mdl-28947956

Palavras-chave

Dabrafenib; Trametinib; impaired-kinase; lung cancer; non-V600 BRAF

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google